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Nanoparticle-mediated delivery of functional macromolecules is a promising method for
treating a variety of human diseases. Among nanoparticles, cell-derived exosomes have
recently been highlighted as a new therapeutic strategy for the in vivo delivery of nucleotides
and chemical drugs. Here we describe a new tool for intracellular delivery of target proteins,
named ‘exosomes for protein loading via optically reversible protein–protein interactions’
(EXPLORs). By integrating a reversible protein–protein interaction module controlled by blue
light with the endogenous process of exosome biogenesis, we are able to successfully load
cargo proteins into newly generated exosomes. Treatment with protein-loaded EXPLORs is
shown to signiﬁcantly increase intracellular levels of cargo proteins and their function in
recipient cells in vitro and in vivo. These results clearly indicate the potential of EXPLORs as a
mechanism for the efﬁcient intracellular transfer of protein-based therapeutics into recipient
cells and tissues.
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D
espite the long list of therapeutic proteins available for
treating various human diseases, the vast majority of
clinically available protein-based drugs, such as cytokines,
hormones and monoclonal antibodies, have been limited to
extracellular mechanisms of action. Intracellular proteins have
been identiﬁed for their potential as biopharmaceutical drugs;
however, many of the challenges associated with intracellular
protein delivery have yet to be solved1. Protein transduction
methods have been proposed to deliver recombinant proteins into
target cells in vitro and in vivo2–4. Although the techniques are
promising, exposure of the protein surface in solution and the low
refolding rate of recombinant proteins in target cells remain
important obstacles for the intracellular delivery of therapeutic
proteins5. Several lipid nanoparticle-mediated protein delivery
methods have been postulated, as has protein encapsulation for
protecting the proteins6,7. However, the absence of a separation
mechanism between cargo proteins and lipid nanoparticles not
only limits the efﬁciency of cytosolic delivery, preparation of these
particles often involves complicated protein puriﬁcation steps.
To address these limitations, we developed an optogenetically
engineered exosome system EXPLORs (exosomes for protein
loading via optically reversible protein–protein interactions) that
can deliver soluble proteins into the cytosol via controlled,
reversible protein–protein interactions (PPIs). Exosomes are
natural cell-derived extracellular vesicles that originate from
internal endocytic compartments and multi-vesicular bodies and
participate in intercellular communication8. Recent studies have
sought to use exosomes as a new method for the in vivo delivery
of siRNA or miRNA to speciﬁc target tissues by systemic
injection9–11. These methods were based on the passive loading of
siRNAs or miRNAs into isolated exosomes by electrophoresis, a
method poorly suited for loading of macromolecular proteins.
Here we propose a novel protein-loading method in which cargo
proteins can be actively loaded into exosomes through
endogenous biogenesis processes, allowing for efﬁcient delivery
into the cytosol of target cells through controllable, reversible
detachment from the exosomes.
To achieve the controllable, reversible loading and delivery of
target proteins into the exosome, we selected a photoreceptor
cryptochrome 2 (CRY2), and CRY-interacting basic-helix-loop-
helix 1 (CIB1) protein module, originally identiﬁed in Arabidopsis
thaliana, which regulates ﬂoral initiation via blue light-dependent
phosphorylation12–14. We induced a transient docking of
CRY2-conjugated cargo proteins to the exosomes by
introducing CIBN (a truncated version of CIB1)14 conjugated
with an exosome-associated tetraspanin protein CD9 and blue
light illumination (Fig. 1a,b). Once the cargo proteins are
introduced into the exosomes via the process of endogenous
biogenesis, they can be detached from CD9-conjugated CIBN by
removal of the illumination source, resulting in their release into
the intraluminal space of the exosomes and enabling efﬁcient
delivery to the cytosolic compartment of target cells.
Results
Light-inducible PPI module for producing EXPLORs. We
generated HEK293T cells that can produce EXPLORs loaded with
mCherry (mCherry:EXPLOR) as a target protein by introducing
vectors for two fusion proteins: CIBN-conjugated enhanced green
ﬂuorescent protein (EGFP)-tagged CD9 (CIBN-EGFP-CD9)
and mCherry-tagged CRY2 (mCherry-CRY2). A single pulse
irradiation of a 488-nm laser induced rapid movement of
mCherry-CRY2 from the cytosolic compartment to the
plasma membrane and intracellular compartments where the
CIBN-EGFP-CD9 proteins were co-localized (Fig. 1c and
Supplementary Fig. 1a). Similar results were obtained by the
introduction of another photoreceptor module GIGANTEA, and
LOV (light-, oxygen- and voltage-sensitive domain) proteins15
and other exosome-enriched tetraspanin proteins, such as CD63,
CD81 and CD82 (Supplementary Fig. 1b,c). We could also
observe light-induced co-localization of mCherry-CRY2 and
CIBN-EGFP-CD9 by a cryo-immunogold electron microscopy
analysis (Supplementary Fig. 2). Introduction of a mutant CRY2,
mutated at an amino acid important in the photolyase function
(D387A)16, abrogated such light-induced co-localization of
CIBN-EGFP-CD9 and mCherry-CRY2 (Supplementary Fig. 3).
On termination of light stimulation, the association between
CIBN-EGFP-CD9 and mCherry-CRY2 dissociated gradually
within 10min, as described previously14 (Fig. 1d,e).
Light-dependent loading of proteins in EXPLORs. For
production of mCherry:EXPLORs, we exposed transiently trans-
fected HEK293T cells with continuous blue light illumination by
installing a 460-nm light-emitting diode (LED; maximum power;
380 mWcm 2) in a CO2 incubator. After 48-h incubation
with blue light illumination, EXPLORs were isolated from the
supernatants by several different methods and conﬁrmed for
the hydrodynamic diameter by dynamic light scattering
(Supplementary Fig. 4 and Supplementary Table 1). Immuno-
blotting results demonstrated that EXPLORs derived from
optogenetically engineered HEK293T cells grown under blue light
illumination contained signiﬁcantly higher amounts of mCherry-
CRY2 protein (84 kDa) than those obtained from cells grown in
the dark (Fig. 2a and Supplementary Fig. 5). In particular, the
highest efﬁciency in protein loading was seen in the power range
from 20 to 50mWcm 2 (Fig. 2b). The threshold power of the
light-induced PPI was measured atB15 mWcm 2 by quantiﬁed
laser stimulation (Supplementary Fig. 6) and at B20 mWcm 2
by the LED light (Supplementary Fig. 7). Continuous irradiation
with blue light for up to 48 h did not induce signiﬁcant cell death
(Supplementary Fig. 8), and we further conﬁrmed that EXPLORs
did not contain detectable DNA fragments typical of apoptotic
bodies (Supplementary Fig. 9a). Because genetically modiﬁed
cells may release exosomes packed with not only the encoded
protein but also genetic material (pDNA and mRNA) encoding
this protein17, we further examined EXPLORs containing
undetectable amounts of plasmid DNA (data not shown) and
mCherry-CRY2 mRNA (Supplementary Fig. 9b). In addition, we
tested the loading efﬁciency of mCherry proteins in EXPLORs in
response to cycles of blue light illumination and darkness. Using a
variety of cycle combinations, we identiﬁed a cycle consisting
of 1min of blue light illumination followed by 1min of darkness
as the optimal condition to produce mCherry:EXPLORs
(Supplementary Fig. 10).
We next examined the loading capacity of EXPLOR technology
by producing ﬁreﬂy luciferase-containing EXPLORs. For the
production of luciferase:EXPLOR, we cloned vectors for ﬁreﬂy
luciferase-conjugated mCherry-CRY2 and conﬁrmed light-
induced PPI with CIBN-EGFP-CD9 by blue light stimulation
with confocal microscopy (Supplementary Fig. 11). First, we
compared luciferase:EXPLORs with a commercialized method for
exosome protein loading, XPACK (System Biosciences, Mountain
View, CA, USA), which is based on the principle that highly
oligomeric, cytoplasmic proteins can be targeted to exosomes by
plasma membrane anchors18,19. We also included exosomes
produced from cells transfected with the luciferase-conjugated
mCherry-CRY2 vector, but not with the CIBN-EGFP-CD9
expression plasmid, to exclude the possibility of nonspeciﬁc
loading of overexpressed cargo proteins into exosomes.
Transfection efﬁciency and expression proﬁle of luciferase-
mCherry fusion proteins were comparable between the different
methods (Fig. 3a,b and Supplementary Fig. 12). For the
quantitative analysis of cargo protein loading into the
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exosomes, we measured luciferase activity using the same
numbers of isolated exosomes (Fig. 3c,d). The results showed
that the loading capacity of EXPLORs was signiﬁcantly higher
than those of the overexpression model of luciferase-mCherry-
CRY2 and a commercialized model for exosome protein
targeting. In our experiment, it was estimated that, on average,
1.4 molecules of luciferase proteins were included in each
exosome obtained by EXPLOR technology (Supplementary
Fig. 13). We also tested another method: ex vitro protein
loading in naive exosomes loaded with recombinant luciferases.
In total, 50 mg of recombinant luciferases (61 kDa) dissolved in
phosphate-buffered saline (PBS) was added to 2 1010 exosomes
derived from HEK293T cells and loaded into exosomes ex vitro
with an extrusion method20. Only 4.4 pg of recombinant protein
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Figure 1 | Generation of engineered EXPLOR. (a) Schematics of DNA constructs used for the production of EXPLOR. (b) Schematic showing fusion
proteins and their proposed action. (c) HEK293T cells were transiently transfected with CIBN-EGFP-CD9 and mCherry-CRY2 expression vectors. The
mCherry ﬂuorescence was imaged before and after 488-nm laser stimulation (15 s in duration, 350mWcm 2). Scale bars, 20mm (5 mm for inset images).
A representative result from at least 10 experiments. (d) HEK293T cells transiently transfected with CIBN-EGFP-CD9 and mCherry-CRY2 were imaged for
time-lapse imaging of mCherry ﬂuorescence for varying time periods (0–12min) after a stimulation (black arrow) of 488-nm light (15 s in duration,
350mWcm 2). Scale bars, 5 mm. A representative result of at least 10 experiments. (e) Quantiﬁcation of mCherry ﬂuorescence in the cytoplasm and
at the plasma membrane. Data are presented as the mean±s.e.m. (n¼ 3).
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Figure 2 | Light-dependent loading of target proteins in EXPLORs. (a) Cells transiently transfected with CIBN-EGFP-CD9 and mCherry-CRY2 expression
vectors were maintained under blue light illumination of varying powers for 48 h. Cell-derived exosomes were subject to immunoblot analysis using
antibodies against mCherry, EGFP and CD63, an exosome marker. A representative result from three independent experiments. (b) The graph presents
densitometry analysis for normalized amount of mCherry-CRY2 protein over CIBN-EGFP-CD9 protein from three independent experiments. Data are
presented as the mean±s.e.m. (n¼ 3), and Tukey’s post hoc test was applied to signiﬁcant group effects (**Po0.01, ***Po0.001) identiﬁed by analysis
of variance.
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was ﬁnally included in the exosomes; thus, the loading capacity of
the ex vitro protein-loading method was estimated to be 40-fold
lower than that of the EXPLOR technology (Supplementary
Fig. 14).
Administration of EXPLORs in vitro and in vivo. HeLa cells
were incubated in the absence or presence of mCherry-loaded
exosomes for 24 h, and tested for analysis with EXPLOR-
mediated protein delivery to recipient cells (Fig. 4a). Consistent
with previous results, EXPLOR-treated cells showed signiﬁcantly
higher ﬂuorescence signals (Fig. 4b). Cryo-immunogold electron
microscopy analysis (Supplementary Fig. 15a) and confocal
microscopy (Supplementary Fig. 15b) revealed that mCherry
proteins were clearly transferred into the cytosolic region of cells
after incubation with mCherry:EXPLORs derived under the ‘light
ON’ condition. Immunoblot analysis demonstrated signiﬁcant
increases in the amounts of intracellular mCherry proteins in
recipient cells after treatment with mCherry:EXPLORs in both a
time- and dose-dependent manner (Supplementary Fig. 15c,d).
To further conﬁrm whether EXPLOR technology can be useful
for the delivery of functional proteins, we cloned vectors for
mCherry-CRY2 proteins fused with Bax and super-repressor IkB
(srIkB) proteins (Supplementary Fig. 16). In the normal
condition, Bax proteins are mainly distributed in the cytosol;
however, on initiation of the apoptotic process, they undergo a
conformation change and move to the mitochondrial membrane,
leading to the release of cytochrome c that subsequently triggers
caspase-dependent apoptosis21–24. As expected, incubation with
Bax-mCherry:EXPLORs induced a rapid release of cytochrome c
from the mitochondria in HeLa cells (Fig. 4c,d). Similarly, the
endogenous nuclear factor-kB (NF-kB) inhibitor IkB proteins
bind to the NF-kB complex in the cytoplasm; however, on
relevant stimulation, IkB is phosphorylated by IkB kinases
and degraded by the ubiquitin–proteasome pathway. Then,
the NF-kB complexes translocate to the nuclei and induce
the expression of survival- and inﬂammation-related genes25.
Super-repressor IkB, a S32A and S36A mutant form of IkB,
is not phosphorylated by IkB kinases, so that srIkB suppresses
the translocation of NF-kB complex even in the presence of
pro-inﬂammatory stimulation26. As expected, treatment with
srIkB-mCherry:EXPLORs signiﬁcantly reduced tumour necrosis
factor-a-induced translocation of the p65 subunit of NF-kB in
HeLa cells (Fig. 4e,f).
Finally, we validated the potential of EXPLOR-mediated
intracellular protein delivery for in vivo application. To test the
intracellular delivery of Cre recombinase containing EXPLORs
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Figure 3 | Comparison of the exosome-loading capacity of target proteins between various protein-loading methods. (a) HEK293T cells were
transiently transfected with luciferase-mCherry-CRY2 expression vector alone, XPack-luciferase-mCherry expression vector or co-transfected with CIBN-EGFP-
CD9 and luciferase-mCherry-CRY2 expression vectors. After 24 h, cells were imaged by ﬂuorescence microscopy for the expression proﬁle of mCherry fusion
proteins. A representative result from ﬁve independent experiments. Scale bars, 20mm. (b) Quantiﬁcation of mCherry ﬂuorescence. Data are presented as
the mean±s.e.m. (n¼ 5), and Tukey’s post hoc test was applied to signiﬁcant group effects identiﬁed by analysis of variance (ANOVA). Control:
untransfected HEK293T cells; OVER: cells transiently transfected with a luciferase-mCherry-CRY2 vector; XP: cells transfected with an XPACK-luciferase-
mCherry vector; and EXPLOR: cells transfected with both luciferase-mCherry-CRY2 and CIBN-EGFP-CD9 vectors. (c) Cells transiently transfected with various
vectors were maintained for 48 h. In the case of EXPLOR-producing cells, cells were maintained in the absence (OFF) or presence (ON) of blue light
illumination; 5 108 particles of the isolated exosomes were analysed for luciferase activity. Data are presented as the mean±s.e.m. (n¼ 3), and Tukey’s
post hoc test was applied to signiﬁcant group effects (**Po0.01, ***Po0.001) identiﬁed by ANOVA. (d) Loading efﬁciency of various protein-loaded
exosomes was calculated by dividing the number of luciferase molecules in exosomes with the number of luciferase molecules in the exosome-producing
cells. Numbers of luciferase molecules were estimated from a standard curve using recombinant luciferase. Data are presented as the mean±s.e.m.
(n¼ 3), and Tukey’s post hoc test was applied to signiﬁcant group effects (***Po0.001) identiﬁed by ANOVA. NS, not signiﬁcant.
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(Cre:EXPLORs), we cloned a vector for Cre-conjugated mCherry-
CRY2 (Cre-mCherry-CRY2) protein. Unlike mCherry-CRY2
protein, Cre-mCherry-CRY2 proteins were predominantly
expressed in the nuclei, and blue light illumination induced
limited translocation of these proteins to the plasma membrane
and intracellular endosomal fractions (Supplementary Fig. 17a).
To avoid unwanted nuclear localization and increase the loading
efﬁciency of Cre-mCherry-CRY2 proteins, cells were maintained
under blue light illumination immediately after transfection.
As expected, continuous light illumination immediately after
transfection markedly enhanced co-localization of Cre-mCherry-
CRY2 proteins with CIBN-EGFP-CD9 (Supplementary Fig. 17b).
The enzymatic activity of Cre recombinase was validated in the
target cells previously transfected with a reporter plasmid
containing a loxP-STOP-loxP sequence upstream of the ZsGreen-
encoding gene. Treatment with Cre:EXPLORs clearly induced
green ﬂuorescence at levels comparable to that of transfection of
pCMV-Cre vectors in various cells including rat embryonic
primary neurons (Supplementary Fig. 18). Because the transient
transfection of primary neurons is extremely inefﬁcient, we next
tested the effect of Cre:EXPLORs on neurosphere-derived
differentiated neuronal cells isolated from transgenic mice
having a loxP-STOP-loxP-EGFP gene. As expected, treatment with
Cre:EXPLORs induced EGFP expression in over 95% of cells; while
treatment with naive EXPLORs had no effect (Fig. 5a,b). Next, we
injected Cre:EXPLORs into the ventrolateral part of the brain of
pCAG-loxP-STOP-loxP-eNpHR3.0-EYFP (enhanced yellow ﬂuor-
escence protein) transgenic mice (Fig. 5c). After 96 h, eNpHR3.0
EYFP proteins were expressed widely near the ventrolateral part in
the brain, and especially were expressed highly in the zona incerta
region (Fig. 5d). Immunohistochemical analyses demonstrated that
the EYFP-positive cells were mainly neurons, indicating that
Cre:EXPLORs worked functionally mainly in neurons in vivo
(Fig. 5e and Supplementary Fig. 19).
Discussion
Although protein transduction and lipid nanoparticle-mediated
protein delivery methods have been proposed for direct protein
delivery into target cells and tissues6,7,27, many obstacles remain
before these methods can be successfully used in vivo, including
low puriﬁcation efﬁciency, failure to separate from nanoparticles
in recipient cells and induction of immune responses against host
immune cells. To address these limitations, we developed an
exosome-based delivery system EXPLORs that can be readily
produced using live cells as a factory via the endogenous
biogenesis of extracellular vesicles (Fig. 6).
This novel method provides signiﬁcant advantages for both
research and clinical applications. First, EXPLORs can carry cargo
proteins without isolation or puriﬁcation of recombinant
proteins. Because EXPLORs contain cell-produced cargo proteins
in unbound soluble form, this approach eliminates many of the
issues such as misfolding of recombinant proteins or separation
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Figure 4 | EXPLOR-mediated intracellular delivery of cargo proteins. (a,b) HeLa cells were incubated in the absence or presence of 5 109 particles of
various isolated exosomes for 24 h and imaged by ﬂuorescence microscopy. The ﬂuorescence intensities of mCherry were quantiﬁed by two imaging
processing tools, ImageJ and Cellproﬁler. Data are presented as the mean±s.e.m. (n¼ 15), and Tukey’s post hoc test was applied to signiﬁcant group effects
(***Po0.001) identiﬁed by analysis of variance (ANOVA). Scale bars, 100mm. (c,d) HeLa cells were incubated in the absence or presence of 0.1mgml 1
mCherry:EXPLORs or Bax-mCherry:EXPLORs for 12 h, and ﬁxed with 4% paraformaldehyde. Then, cytochrome c was stained with an antibody conjugated
with Alexa Fluor 647 and imaged by confocal microscopy. The ratios of cytochrome c localization were analysed by cell counting. Data are presented as the
mean±s.e.m. (n¼ 3), and Tukey’s post hoc test was applied to signiﬁcant group effects (**Po0.01) identiﬁed by ANOVA. Scale bars, 20mm. (e) HeLa cells
were incubated in the absence or presence of 0.1mgml 1 mCherry:EXPLORs or srIkB:EXPLORs for 12 h, treated with 10 ngml 1 tumour necrosis factor- a
(TNF-a) for an additional 30min, and ﬁxed with 4% paraformaldehyde. NF-kB p65 was stained with an antibody conjugated with Alexa Fluor 488 and
imaged by confocal microscopy. (f) The nuclear extracts of cells were assayed for the DNA-binding activity of p65/c-Rel (NF-kB). Data are presented
as the mean±s.e.m. (n¼ 3), and Tukey’s post hoc test was applied to signiﬁcant group effects (**Po0.01) identiﬁed by ANOVA. Scale bars, 20mm.
NS, not signiﬁcant.
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of nanoparticles and cargo proteins in the target cells. Second,
EXPLORs can be readily and easily produced once the
appropriate EXPLOR-producing donor cells have been selected
from genetically engineered cells. By simply irradiating with a
blue light, we can generate EXPLORs loaded with speciﬁc cargo
proteins, including those derived from other cell types. This stable
production of EXPLORs from genetically engineered cells
has great potential for the commercialization of standardized
exosome-based protein therapeutics. Finally, EXPLORs are
compatible with many personalized medicine-based therapeutic
approaches. By modifying patient-derived cells to produce
EXPLORs28, we would be able to manufacture patient-
customized drug delivery systems with reduced risk of
triggering host immune responses, opening a new paradigm for
personalized protein-based therapeutics.
In the present study, we showed that exosomes from cells
transiently transfected with a luciferase-mCherry-CRY2 vector
rarely had luciferase molecules; however, EXPLORs that were
derived from cells transfected with luciferase-mCherry-CRY2 and
CIBN-EGFP-CD9 vectors under the light OFF condition had
considerable numbers of luciferase molecules. The difference
between the two conditions was CIBN-EGFP-CD9 expression.
Recently, one research group showed that overexpressed
CRY2-conjugated proteins have a weak binding activity with
CIBN-conjugated proteins in the normal state29. Thus, we suggest
that unintended binding of mCherry-CRY2 to CIBN-EGFP-CD9
could be partially responsible for loading of mCherry proteins
into exosomes under the light OFF condition.
EXPLORs had the highest efﬁciency in protein encapsulation
under blue light illumination in the power range of
20–50 mWcm 2, not at the strongest power (200 mWcm 2).
We found that incubation of cells under blue light illumination at
a power of 200 mWcm 2 did not induce signiﬁcant cell death;
thus, cell death was not the cause of decreased protein loading
efﬁciency according to strong light. We presumed that
aggregation of CRY2 proteins by strong blue light might disturb
the light-induced PPI between mCherry-CRY2 and CIBN-EGFP-
CD9 proteins16. To address this, we used CRY2 fusion proteins
conjugated with Cre recombinase. Unlike other CRY2 fusion
proteins conjugated with cytosolic proteins, Cre-mCherry-CRY2
proteins were expressed mainly in the nuclei. Because aggregated
forms of Cre-CRY2 proteins cannot diffuse readily through
nuclear membranes, we can readily study the effect of light
intensity on the aggregation of CRY2 proteins by simply
analyzing the subcellular localization of Cre-mCherry-CRY2
proteins. As expected, we observed that the stronger the
blue light illuminated, the more Cre-mCherry-CRY2 stayed in
the cytosolic compartment, rather than inside the nucleus,
conﬁrming that CRY2-fusion proteins can form aggregates
under high-intensity light conditions (Supplementary Fig. 20).
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by ventrolateral injection. (d) Brain slices of EXPLOR-injected transgenic mice were ﬁxed with 4% formaldehyde and imaged by ﬂuorescence microscopy.
Green ﬂuorescence indicates eNpHR3.0-EYFP protein expression and blue ﬂuorescence indicates cell nuclei. Inset images showed confocal microscopy
images of the detailed cellular eNpHR3.0-EYFP expression in EXPLOR-administered mouse neurons of the zona incerta (ZI) region. Scale bars, 500mm
(50mm for inset confocal images). Hip, hippocampus; Th, thalamus. A representative of two independent experiments. (e) Representative image of
NeuN/GFAP immunohistochemistry of the brain. Pink, neuronal-speciﬁc nuclear protein (NeuN)-positive neurons; Red, glial ﬁbrillary acidic protein
(GFAP)-positive astrocyte cells. Objective lens, 40. Scale bar, 20mm. NS, not signiﬁcant.
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We found that one or two cargo molecules were contained in
one particle of EXPLOR on average; however, this limited loading
efﬁciency might still have room for improvement. In the present
study, we used fusion proteins of ﬂuorescence reporters with both
the CIBN and CRY2 protein for better tracking of target proteins.
Because we have conﬁrmed that target proteins conjugated with
CRY2 can be successfully recruited to engineered exosomes,
direct conjugation of cargo proteins or tetraspanins to CRY2 or
CIBN proteins without ﬂuorescent reporter proteins can further
decrease the molecular size of cargo proteins and subsequently
improve loading efﬁciency of cargo proteins into EXPLORs. In
addition, the current strategy using two vectors can further be
optimized by using a one-vector system, by introducing an
internal ribosome entry site. These approaches might increase the
transfection efﬁciency, as well as the loading of cargo proteins
into EXPLORs.
In the present study, we developed a novel protein carrier
EXPLOR that has a higher loading capacity and delivery
efﬁciency than previous methods for protein-loaded exosomes.
Also, we demonstrated the intracellular delivery of mCherry, Bax,
super-repressor IkB protein and Cre enzyme as functional
proteins into the target cells in vitro and into brain parenchymal
cells in vivo. Many intracellular proteins, such as transcription
factors, signal transducers and enzymes can also be
attractive targets for EXPLOR-based therapeutics. Using our
EXPLOR technique, we might be able to design various
EXPLOR-producing cells that would be equivalent to monoclonal
antibody-producing hybridoma cells for protein-based
therapeutics targeting intracellular events.
Methods
Cell culture. HEK293T human embryonic kidney cells (CRL-3216, ATCC,
Manassas, VA, USA), HT1080 cells (CCL-121, ATCC) and HeLa cells (CCL-2,
ATCC) were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Welgene, Seoul, Korea) containing 10% fetal bovine serum (FBS; Gibco,
Gaithersburg, MD, USA) and 1% penicillin–streptomycin (Gibco).
Blue LED-installed incubator. The 460-nm LED bars for plant growth
(TG-TECH, Asan, Korea) were installed in a CO2 incubator for illuminating cells
with blue light. For controlling the light power of the blue LED, a LED dimmer
(Hyeonju LED, Seoul, Korea) was added. Automatic control of the on/off cycle
was achieved using an inﬁnite-iteration timer attached to the power source
(Seojun Electronics, Seoul, Korea). To equally illuminate blue light on the cells,
a polycarbonate plate of 3mm width (BEST ACRYLIC, Incheon, Korea) was added
under the blue LED bars as a light diffuser. An optical power meter 8230E
(ADCMT, Tokyo, Japan) was used to assess the LED illumination power.
Reagents. Primary antibody sources were as follows: mouse monoclonal mCherry
antibody (diluted 1:1,000 for western blotting, 1:50 for EM, ab125096), rabbit
monoclonal CD9 antibody (diluted 1:50 for EM, ab92726) and NF-kB antibodies
(diluted 1:1,000 for immunocytochemistry, ab16502) were obtained from Abcam
(Cambridge, MA, USA); CD63 (diluted 1:1,000 for western blotting, sc-15363) and
GAPDH (diluted 1:4,000 for western blotting, sc-25778) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA); cytochrome c antibody (diluted
1:1,000 for immunocytochemistry, 556432) was from BD biosciences (San Jose,
CA, USA); and the GFP antibody (diluted 1:1,000 for western blotting, 2555) was
from Cell Signaling Technology (Beverly, MA, USA). Secondary antibody sources
were as follows: anti-rabbit (sc-2004) and mouse secondary antibody (sc-2005)
were obtained from Santa Cruz Biotechnology, and Alexa Fluor 647 goat
anti-mouse IgG (Hþ L) antibody (diluted 1:1,000 for ICC, A-21235) and Alexa
Fluor 488 goat anti-rabbit IgG (Hþ L) antibody (diluted 1:1,000 for ICC, A-11008)
were purchased from Thermo Fisher Scientiﬁc (Wilmington, DE, USA).
Plasmids and transfection. All plasmids and PCR primers used in this study are
listed in Supplementary Table 2. pCMV-CIBN-EGFP and pCMV-mCherry-CRY2
(codon-optimized for expression in mammalian cells) were generated30. To
generate the pCMV-CIBN-EGFP-CD9 construct, a sequence encoding full-length
CIBN-EGFP was PCR-ampliﬁed from CIBN-EGFP constructs, and a gene encoding
CD9 was PCR-ampliﬁed from the LN215 cDNA library using gene-speciﬁc
primers. For the CIBN-EGFP-CD9 construct, the ﬁrst fragment (CIBN-EGFP-)
contained an EcoRI site, a sequence encoding the full-length CIBN-EGFP, and a
sequence encoding a ﬂexible linker (SGGGGSGGGGSGGGGS). The second PCR
fragment contained a ﬂexible linker, a sequence encoding full-length CD9, and a
XhoI site, followed by 15 base pairs of homology to the pcDNA3.1(þ ) (Invitrogen,
Carlsbad, CA, USA) vector. To construct exosomal membrane-targeting
sequence-tagged mCherry, the mCherry-encoding gene was ampliﬁed from an
mCherry-CRY2 vector and ligated into an EcoRI site of XPack CMV-XP-MCS-
EF1-Puro Cloning Lentivector (System Biosciences, Mountain View, CA, USA).
To assemble pCMV-Cre-mCherry-CRY2, genes encoding Cre were PCR-ampliﬁed
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Figure 6 | Schematic diagram of EXPLOR technology. In EXPLOR-producing donor cells, CRY2 protein was fused to a cargo protein, and CIBN was
conjugated with a representative marker of exosomes, CD9 protein. Blue light illumination induces the reversible PPI between CIBN and CRY2 fusion
proteins. With continuous blue light irradiation, the cargo proteins are guided to the inner surface of the cell membrane or the surface of early endosomes.
Mature multi-vesicular bodies (MVBs) then readily secrete cargo protein-carrying exosomes (EXPLORs) from the cells by membrane fusion with the
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into target cells via membrane fusion or endocytosis processes. Bottom grey boxes highlight the essential steps from EXPLORs biogenesis to target
cell delivery.
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from the pCMV-Cre vector (Addgene plasmid 11916) using gene-speciﬁc primers.
For the construct, the ﬁrst fragment (Cre-) contained an EcoRI site, a sequence
encoding full-length Cre except a stop codon and a sequence encoding a ﬂexible
linker (SAGGPPVAT). The second PCR fragment (mCherry-CRY2) contained the
ﬂexible linker, a sequence encoding full-length mCherry-CRY2 and a XhoI site,
followed by 15 base pairs with homology to the pcDNA3.1(þ ) vector.
A pCAG-loxP-STOP-loxP-ZsGreen plasmid was obtained from Addgene
(plasmid 51269). The Bax gene was ampliﬁed from the LN215 cDNA library,
super-repressor IkB was obtained from Addgene (plasmid 15294) and ﬁreﬂy
luciferase gene was obtained from the pGL4.11[luc2P] vector (Promega, Madison,
WI, USA). Cells were transfected with Effectene Transfection Reagent (Qiagen,
Valencia, CA, USA) at a density of 50–80% conﬂuence, according to the
manufacturer’s protocol.
Microscopy for cell imaging. Live cells were imaged using a Zeiss LSM 510
confocal microscope with a  63 Apochromat 1.0 numerical aperture (NA)
objective (Carl Zeiss, Thornwood, NY, USA). Laser light (488 nm) was used to
induce dimerization between CRY2PHR and CIBN and to image GFP fusion
proteins; a 594- nm laser was used to image mCherry-fusion proteins. Z-stack and
time-lapse imaging were also performed using the confocal microscope, and the
three-dimensional reconstruction and real-time images were processed using
ImageJ software. An environmental chamber (Harvard Apparatus, South Natick,
MA, USA) enclosing the microscope stand was used to maintain the temperature at
37 C with 5% CO2 during live cell imaging. For ﬂuorescence microscope imaging,
cells were ﬁxed with 4% paraformaldehyde at 30min and imaged using a Zeiss
Axiovert 200M ﬂuorescence imaging microscope with  10 Plan-NeoFluar 0.3
NA objective and a 20 Plan-NeoFluar 0.5 NA objective (Carl Zeiss). The
quantiﬁcation of cell ﬂuorescence was analysed using the Cellproﬁler software
(Broad Institute, Cambridge, MA, USA).
Exosome isolation. Cells were collected and transferred to fresh FBS-free DMEM
(Welgene) containing 1% penicillin–streptomycin (Gibco) or DMEM containing
1% penicillin–streptomycin and 10% exosome-depleted FBS31. After 48 h, medium
was collected and centrifuged at 3,000g for 15min to remove cellular debris.
Exosome isolation was performed by precipitation or ultracentrifugation. For
precipitation, the supernatant was transferred to a sterile vessel and the appropriate
volume of ExoQuick-TC Exosome Precipitation Solution (System Biosciences) was
added. Samples were mixed by inverting or ﬂicking the tube and then refrigerated
overnight. After 24 h, the ExoQuick-TC mixture was centrifuged (1,500g, 30min).
After centrifugation, the supernatant was removed and the mixture was spun down
again (1,500g, 5min). All traces of ﬂuid were removed by aspiration, and the
exosome pellet was resuspended in 100ml PBS by passaging 5–10 times through a
sterile 27-gauge needle (BD Biosciences, San Jose, CA, USA). Then, the suspended
exosomes were ﬁltered through a syringe ﬁlter (0.2 mm; Sartorius, Goettingen,
Germany) to prevent aggregation of exosomes and to remove Exoquick polymers.
For ultracentrifugation-based puriﬁcation of exosomes, supernatants were
transferred to an appropriate vessel for the MF-600 ultracentrifuge (Hanil Science
Industrial, Incheon, Korea) and centrifuged (120,000g, 2 h). After centrifugation, all
traces of ﬂuid were removed by aspiration, and the exosome pellet was resuspended
in 100ml PBS by passaging 5–10 times through a sterile 27-gauge needle (BD
Biosciences). The suspended exosomes were then ﬁltered through a syringe ﬁlter
(0.2mm, Sartorius). The concentration of suspended exosomes was measured using
a Nanodrop ND-1000 spectophotometer (Thermo Scientiﬁc, Wilmington, DE,
USA). The size of the suspended exosomes was measured with a Zetasizer ZS90
dynamic light scattering machine, operating in intensity mode using a 640-nm
HeNe laser (Malvern Instruments, Worcestershire, UK). The number of exosome
particles was measured by nanoparticle-tracking analysis with a Nanosight NS300
(Malvern Instruments).
Immunoblotting. Collected cells or isolated exosomes were washed in ice-cold
PBS, and suspended in adjusted volumes of buffer, provided with the M-Per
mammalian protein extraction kit (Pierce, Rockford, IL, USA). The cells were
incubated on ice for 30min, and the lysates were then cleared by centrifugation at
10,000g for 10min. Lysates were then separated by 12% SDS–polyacrylamide gel
electrophoresis, transferred to nitrocellulose membranes (Invitrogen, Carlsbad, CA,
USA), and incubated with the appropriate antibodies. The immunoblots were
imaged using an enhanced chemiluminescence system (Ab Frontier, Seoul, Korea).
Full scans of western blots are in Supplementary Fig. 5.
Luciferase activity assay. Collected cells or isolated exosomes were washed in
ice-cold PBS, and suspended in adjusted volumes of buffer provided with Reporter
Lysis Buffer (Promega). A total volume of 20 ml of samples was loaded in a black
96-well plate (SPL Life Sciences, Pocheon, Korea), and 100 ml of Luciferase Assay
Reagent (Promega)-reconstituted substrate was added to each reaction manually.
Measurements were performed using a Berthold LB942 TriStar2 multidetection
microplate reader (Berthold, Bad Wildbad, Germany). The integration time was set
at 1 s for all measurements. To perform a quantitative luciferase assay, QuantiLum
Recombinant Luciferase (Promega) was used to obtain a standard curve. On the
basis of the standard curve, a ﬁtting curve and the number of luciferase molecules
were calculated.
Measurement of DNA-binding activity of NF-jB. Nuclear extracts (5 mg) were
assayed for the binding activity of p65/c-Rel (NF-kB) using the TransAM NF-kB
assay kit (ActiveMotif, Carlsbad, CA, USA) according to the manufacturer’s
manual32.
Culture of differentiated neurosphere-derived cells. The cerebral cortex tissues
from E12.5 Rosa-EGFP reporter mice (The Jackson Laboratory, Bar Harbor, Maine,
USA) were dissected from the brain33. Isolated tissues were incubated with
Accutase (Innovative Cell Technologies, San Diego, CA, USA) for 5min at 37 C.
Cells were grown on an ultralow attachment surface and maintained as
neurospheres for 4 days in the presence of basic ﬁbroblast growth factor
(20 ngml 1; R&D systems, Minneapolis, MN, USA) and epidermal growth factor
(20 ngml 1; Invitrogen) in DMEM/F12 (Gibco) media containing 1% N2 (Gibco),
2% B27 (Gibco) supplements, and 1% penicillin–streptomycin (Gibco). For
differentiation, neurospheres were dissociated and cultured on 18-mm cover glass
coated with poly-D-lysine (100mgml 1) and laminin (5mgml 1) with removal
of epidermal growth factor/basic ﬁbroblast growth factor. On the seventh day of
differentiation, puriﬁed exosomes were treated to the cells and maintained the
culture for an additional 3 days. For immunocytochemistry, cells were then ﬁxed
with 4% paraformaldehyde and immunostained with anti-b-Tubulin III (Tuj1)
(diluted 1:1,000, Sigma-Aldrich, St. Louis, MO, USA, T2200), anti-GFP (diluted
1:1,000, Abcam, ab290) and counterstained with Hoechst 33342 (Invitrogen).
Images were acquired on an EVOS FL cell imaging system (Invitrogen) with a
EVOS AMEP 4624 (Plan Fluor  20/0.45) objective lens.
Animals. Animal care and handling were performed according to the guidelines of
the Animal Care and Use Committee of the Korea Advanced Institute of Science
and Technology (KAIST, Daejeon, Korea). Loxp-stop-loxp-eNpHR3.0-EYFP
transgenic mice (The Jackson Laboratory) were generated by mating heterozygous
transgenic and wild-type mice (Males, 22 weeks, C57BL/6J background) in a
speciﬁc-pathogen-free environment. All mice were maintained on a 12/12-h
light/dark cycle (light cycle beginning at 6:00) at a temperature of 23 C. Food
and water were supplied ad libitum.
Stereotactic injection of EXPLORs in mouse brain. All mice were anaesthetized
with avertin (20mgml 1 of tribromoethanol, 20 ml g 1 intraperitoneal,
Sigma-Aldrich, Milwaukee, WI, USA) and placed in a stereotaxic apparatus (David
Kopf Instruments, Tujunga, CA, USA). All injections were delivered at a rate of
0.3–0.8 ml min 1 via a 10-ml Hamilton syringe (Hamilton Co., Reno, NV, USA)
and an injection needle (33-gauge NanoFil Needle Assortment, blunt; WPI,
Worcester, MA USA) using a syringe pump (KD Scientiﬁc, Holliston, MA, USA).
For expression of eNpHR3.0-EYFP, control EXPLORs and Cre:EXPLORs were
prepared. In total, 500 mg of EXPLORs were injected into the ventrolateral part of
the brain in each mouse ( 2.8mm anteroposterior,  2.2 mediolateral and
3.8 dorsoventral). At 5 days after transfection, mice were killed for visualization.
Histology and immunohistochemistry of mouse brain. Mice were deeply
anaesthetized with avertin (20mgml 1 of tribromoethanol, 20 ml g 1
intraperitoneal, Sigma-Aldrich) and perfused ﬁrst with heparin and then with 4%
formaldehyde diluted in PBS. Brains were removed and post-ﬁxed overnight at
4 C. Coronal sections (40-mm thick) were acquired using a vibratome (Leica
VT1000S; Leica, Rockleigh, NJ, USA) and collected in PBS. Slices were mounted on
glass slides with Vectashield mounting medium containing 40 ,6-diamidino-2-
phenylindole (DAPI; Vector Labs, Peterborough, UK). Fluorescent images
(low magniﬁcation) were acquired with an Axio Imager 2 ﬂuorescent microscope
(Carl Zeiss). Confocal images were acquired with a LSM780 confocal microscope
(Carl Zeiss) equipped with a Plan-Apochromat  20/0.8 M27 objective. Brain
sections were incubated in PBS with 0.5% Triton X-100 (Sigma-Aldrich) for 30min
at room temperature. After washing in PBS for 10min, sections were incubated in a
blocking solution composed of 0.5% bovine serum albumin and 0.25% Triton-X
100 for 1 h at room temperature. For NeuN/GFAP immunostaining, sections were
incubated with mouse anti-NeuN primary antibody (MAB377; Millipore) and
chicken anti-GFAP primary antibody (AB5541; Millipore), diluted 1:1,000 in
PBS containing 0.25% Triton X-100, for 15 h at room temperature. After washing
twice in PBS for 5min each, sections were incubated with ﬂuorescein Alexa
647-conjugated anti-mouse IgG secondary antibody (Jackson ImmunoResearch,
West Grove, PA, USA) and Alexa 555-conjugated anti-chicken IgG secondary
antibody (Jackson ImmunoResearch), and diluted 1:300 in PBST for 1 h at room
temperature. Sections were washed twice in PBS for 5min each and mounted on
glass slides with Vectashield mounting medium containing DAPI (Vector Labs).
Statistical analyses. Data are presented as means±s.e.m. The signiﬁcance of the
difference between two independent samples was determined using Student’s t-test.
Groups were compared using one-way analysis of variance, with Tukey’s post hoc
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test applied to a signiﬁcant main effect. All data were normally distributed and the
variances were similar between the groups being statistically compared. Sample size
was based on previous experience with experimental variability, and no statistical
method was used to predetermine sample or animal sizes. No samples or animals
were excluded from the analysis. All experiments were not randomized. The
investigators were not blinded to allocation during experiments or outcome
assessment.
Data availability. All data supporting the ﬁndings in this study are included in the
article, either in the main ﬁgures or in the Supplementary Information ﬁles.
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